FKnol.com

Financial Knowledge & Information Portal

AbbVie (ABBV) Company Profile

Updated Dec 2, 2019
AbbVie has the following business profile:
Company's Full Name:AbbVie Inc.
Short Name:AbbVie
Trading Ticker Symbol:ABBV
Primary Exchange:NYSE
Headquarter City/Country:North Chicago, Illinois
Primary Industry Sector:Health Care
Seconday Sub-sector:Major Pharmaceuticals
Main Business Areas: Health Care, Major Pharmaceuticals, Major Drug Manufacturers
Dividend Payments:Dividend History

Market and Trading Information for AbbVie

The following details were available for trading and market data about the stock of AbbVie as of writing:
Current Share Price:$87.03
Previous Year's Closing Price:$92.19
Percentage Price Change (YTD):-5.6%
Market Cap:$128.7 billion
52-week Price Range:$62.66 - $94.98
Dividend Per Share:$4.17
EPS (TTM):2.18
Price-Earnings (Trailing):39.98
Price-Earnings (Forward):8.93

Company Profile and Business Description for AbbVie

AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

HUMIRA is a biologic therapy administered as a subcutaneous injection. It is approved to treat the autoimmune diseases, such as Rheumatoid arthritis (moderate to severe), Psoriatic arthritis, Ankylosing spondylitis, Adult Crohn's disease (moderate to severe), Plaque psoriasis (moderate to severe chronic), Ulcerative colitis (moderate to severe), Pediatric Crohn's disease (moderate to severe), Hidradenitis Suppurativa (moderate to severe), non-infectious intermediate, posterior and panuveitis, and Juvenile idiopathic arthritis (moderate to severe polyarticular) in North America and the European Union. It is also approved to treat the autoimmune diseases, such as Axial spondyloarthropathy and Pediatric enthesitis-related arthritis in the European Union. It is also approved in Japan for the treatment of intestinal Behcet's disease.

AbbVie's oncology products targets cancers, including hematologic and solid cancers. These products include IMBRUVICA (ibrutinib) and Venclexta (venetoclax). IMBRUVICA is an oral and once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). It is approved for the treatment of patients with chronic lymphocytic leukemia (CLL). It is also approved for the treatment of patients with mantle cell lymphoma (MCL), who have received at least one prior therapy. It also treats patients with relapsed/refractory marginal zone lymphoma (MZL). Venclexta is approved to treat people with chronic lymphocytic leukemia (CLL). It is approved for the treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth.

The Company's Virology products address the needs for patients with the HCV and HIV-1. Its HCV product, VIEKIRA PAK (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), which is an all-oral, short-course, interferon-free therapy, with or without ribavirin, for the treatment of adult patients with genotype 1 chronic HCV, including those with compensated cirrhosis. In Europe, its HCV treatment is marketed as VIEKIRAX + EXVIERA and is approved for use in patients with genotype 1 and genotype 4 HCV. AbbVie's TECHNIVIE (ombitasvir, paritaprevir and ritonavir) is also approved for use in combination with ribavirin for the treatment of adults with genotype 4 HCV infection in the United States.

The Company's additional virology products include Kaletra (lopinavir/ritonavir), Norvir (ritonavir) and Synagis (palivizumab). Kaletra is a prescription anti-HIV-1 medicine that contains two protease inhibitors: lopinavir and ritonavir. It is used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1. Norvir is a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Synagis is a product marketed by AbbVie outside of the United States that protects at-risk infants from severe respiratory disease caused by respiratory syncytial virus (RSV).

The Company's metabolic and hormone products target various conditions, including testosterone deficiency due to certain underlying conditions, exocrine pancreatic insufficiency and hypothyroidism. These products include AndroGel (testosterone gel), Creon (pancrelipase) and Synthroid (levothyroxine sodium tablets). AndroGel is a testosterone replacement therapy for males diagnosed with symptomatic low testosterone due to certain underlying conditions. Creon is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, a condition that occurs in patients with cystic fibrosis, chronic pancreatitis and several other conditions. Synthroid is used in the treatment of hypothyroidism. It has the rights to sell these products only in the United States.

AbbVie's endocrinology product, Lupron (leuprolide acetate), which is also marketed as Lucrin and Lupron Depot, is a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily subcutaneous injection and one-month, three-month, four-month and six-month intramuscular injection.

The Company's other products include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab). Its levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease is marketed as Duopa in the United States and as Duodopa outside of the United States. Sevoflurane, which is sold under the trademarks Ultane and Sevorane, is an anesthesia product that it sells around the world for human use. ZINBRYTA is a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (MS).

1 N Waukegan Rd

Peer / Competitor Companies of Major Pharmaceuticals Sector

Along with AbbVie Inc., the following other peer (competitor) companies also exist within the same Major Pharmaceuticals - Health Care sector whose company profile and dividend history is as follows:

▶ Abbott Labs (ABT): Abbott Laboratories, incorporated on March 6, 1900, is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical ....See Detailed Company Profile  and Dividend History.

▶ Abeona Therapeutics (ABEO): Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., incorporated on June 22, 1989, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Companys lead ....See Detailed Company Profile  and Dividend History.

▶ Abeona Therapeutics (ABEOW): ....See Detailed Company Profile  and Dividend History.

▶ AC Immune SA (ACIU): AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimers and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinsons, and ....See Detailed Company Profile  and Dividend History.

▶ ACADIA Pharma (ACAD): ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. The ....See Detailed Company Profile  and Dividend History.

▶ Acasti Pharma (ACST): Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. The Company is involved ....See Detailed Company Profile  and Dividend History.

▶ AcelRx Pharma (ACRX): AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company ....See Detailed Company Profile  and Dividend History.

▶ Achaogen (AKAO): Achaogen, Inc., incorporated on November 26, 2002, is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative ....See Detailed Company Profile  and Dividend History.

▶ Achillion Pharma (ACHN): Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and ....See Detailed Company Profile  and Dividend History.

▶ Aclaris Therapeutics (ACRS): Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological ....See Detailed Company Profile  and Dividend History.

▶ Actinium Pharma (ATNM): Actinium Pharmaceuticals, Inc. (Actinium), incorporated on March 20, 2013, is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its ....See Detailed Company Profile  and Dividend History.

▶ Acura Pharma (ACUR): Acura Pharmaceuticals, Inc., incorporated on April 10, 1935, is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication ....See Detailed Company Profile  and Dividend History.

▶ Adamas Pharma (ADMS): Adamas Pharmaceuticals, Inc., incorporated on November 15, 2000, is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic ....See Detailed Company Profile  and Dividend History.

▶ Adamis Pharma (ADMP): Adamis Pharmaceuticals Corporation, incorporated on April 22, 2004, is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products ....See Detailed Company Profile  and Dividend History.

▶ Aduro Biotech (ADRO): Aduro Biotech, Inc., incorporated on May 5, 2011, is an immunotherapy company. The Company focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, ....See Detailed Company Profile  and Dividend History.

▶ Advanced Accelerator Applications (AAAP): Advanced Accelerator Applications S.A., incorporated on March 1, 2002, is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace ....See Detailed Company Profile  and Dividend History.

▶ Advaxis (ADXS): Advaxis, Inc., incorporated on February 28, 2002, is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are ....See Detailed Company Profile  and Dividend History.

▶ Advaxis (ADXSW): ....See Detailed Company Profile  and Dividend History.

▶ Aeglea BioTherapeutics (AGLE): Aeglea BioTherapeutics, Inc., incorporated on December 16, 2013, is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to ....See Detailed Company Profile  and Dividend History.

▶ AEterna Zentaris (AEZS): Aeterna Zentaris Inc., incorporated on October 12, 1990, is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and womens health. The Company operates through the ....See Detailed Company Profile  and Dividend History.

... See Full List of All Stocks of Major Pharmaceuticals Sector.

Stock List of Other Health Care Sub-sectors

▶ Stocks of Sector

▶ Stocks of Biotech Sector

▶ Stocks of Biotech Apparatus Sector

▶ Stocks of Biotech Diagnostics Sector

▶ Stocks of Biotech Products Sector

▶ Stocks of Biotech Research Sector

▶ Stocks of Drug Delivery Sector

▶ Stocks of Drug Development Sector

▶ Stocks of Drug Manufacturer Sector

▶ Stocks of Health Care Sector

▶ Stocks of Health Care Equipment and Services Sector

▶ Stocks of Hospital and Nursing Management Sector

▶ Stocks of Industrial Specialties Sector

▶ Stocks of Major Pharmaceuticals Sector

▶ Stocks of Medical Dental Instruments Sector

▶ Stocks of Medical Electronics Sector

▶ Stocks of Medical Nursing Services Sector

▶ Stocks of Medical Products Sector

▶ Stocks of Medical Specialities Sector

▶ Stocks of Ophthalmic Goods Sector

▶ Stocks of Other Pharmaceuticals Sector

▶ Stocks of Precision Instruments Sector


Stock List of Other Top-level Sectors

▶ Stocks of Sector

▶ Stocks of Basic Industries Sector

▶ Stocks of Basic Materials Sector

▶ Stocks of Capital Goods Sector

▶ Stocks of Communication Services Sector

▶ Stocks of Consumer Cyclical Sector

▶ Stocks of Consumer Defensive Sector

▶ Stocks of Consumer Durables Sector

▶ Stocks of Consumer Non-Durables Sector

▶ Stocks of Consumer Services Sector

▶ Stocks of Energy Sector

▶ Stocks of Finance Sector

▶ Stocks of Financial Services Sector

▶ Stocks of Health Care Sector

▶ Stocks of Industrials Sector

▶ Stocks of Miscellaneous Sector

▶ Stocks of Public Utilities Sector

▶ Stocks of Real Estate Sector

▶ Stocks of Services Sector

▶ Stocks of Technology Sector

▶ Stocks of Transportation Sector

▶ Stocks of Utilities Sector